On 23 August 2025, a public post challenged an apparent contradiction: reported restrictions on finance for oncology treatment alongside continued approvals for large consumer-import credits.

The post argued that applications connected to medicine and treatment faced several layers of control while substantial official dollars continued to finance products such as ketchup, mayonnaise, sugar and frozen poultry.

One rule

should govern every allocation: documented need, verified delivery, transparent beneficiaries and a measurable public result.

The allegation and the evidence gap

The contemporaneous media copy records Algarj’s allegation that questionable or fictitious credits were approved while oncology finance was stopped. The surviving copy does not include the applications or official decision file needed to prove that claim independently.

That limitation defines what authorities should publish: medical applications received, approved, rejected or delayed, the criteria applied, and the equivalent record for major consumer imports.

Priority is a policy, not a slogan

Foreign currency is scarce enough that every allocation carries an opportunity cost. That does not mean consumer imports must stop; it means the ranking rule must be visible.

Medical finance also requires procurement verification, pricing discipline and proof of delivery. The answer is equal, rapid scrutiny — not a weaker standard for one channel and a harder one for another.

The disclosure that would settle the argument

A monthly dashboard could show applications by sector, approval rate, processing time, value, reason for rejection and delivery status. Health categories could distinguish medicines, equipment, overseas treatment and oncology care.

Two allocation systems must be compared on the same basis

A fair comparison cannot place a delayed treatment request beside an approved consumer credit without defining the stage of each. Health financing may involve public procurement, overseas-treatment committees or bank transfers, while trade credits follow a different legal and documentary route. The common denominator is scarce foreign currency, not identical procedure.

Authorities should therefore publish applications, decisions and execution for both channels over the same dates. Only then can the public test whether medical need faced a systematically higher barrier or whether the reported case reflected missing documents, budget authority, pricing or another stated reason.

Medical priority still requires procurement discipline

Giving oncology a high social priority does not remove the need to verify patient eligibility, supplier, medicine registration, unit price, treatment provider and delivery. Weak control can waste health dollars without treating a patient. The answer to scarcity is faster evidence-based review, not exemption from review.

Equally, the fact that food products are ordinary imports does not make every credit low priority. Policy should distinguish staples, industrial inputs and discretionary goods with published criteria rather than relying on rhetorical labels.

What would prove unequal treatment

Evidence would include the dated medical applications, requested amounts, supporting decisions, correspondence, processing time and reason for delay or rejection, compared with consumer-credit files accepted in the same window. Without those records, the original claim remains an important allegation that the published evidence cannot independently close.

The right institutional response is a reasoned record, not a general denial. If the decisions were lawful, the data will show the rule applied. If a priority channel stalled while lower-ranked uses advanced without explanation, the same data will reveal the inconsistency.

A public priority dashboard

A monthly dashboard should separate oncology medicines, equipment, domestic treatment and overseas care, and report applications, approvals, execution, waiting time, beneficiaries served and delivered value. Consumer imports should be grouped by transparent policy class rather than selectively named products.

This would allow Parliament, auditors, patients and traders to debate the allocation rule using the same denominator. It would also make exceptional delays visible before they become crises or accusations.

Historical note: This reconstruction preserves the statement as made in August 2025 and distinguishes the author’s allegation from independently verified fact.